|
The infomation contained in the above links in part comes from these references:
Armstrong M, Daly AK, Blennerhassett R, et al: Antipsychotic drug induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry; 170:23
-6, 1997
Barak Y, Swartz M, Shamir E, et al: Vitamin E (alpha-tochopherol) in the treatment of dyskinesia: a meta-analysis. Ann Clin Psychiatry; 10(3):101-5, 1998
Diederich NJ, Goetz CG: Drug induced movement disorders. Neuro Clin North Am 16(1) 125-139,1998
Kiriakakis V, Bhatia KP, Quinn NP, et al: The natural history of tardive dystonia. Brain; 121(pt11):2053-66, 1998
Miller LG, Jankovic J, Kane JM, et al. In: Joseph AB, Young RR eds. Movement Disorders in Neurology and Neuropsychiatry, Part 1 chapters 1-21; Blackwell Scientific
Publications, 1992
Nisijima K, Shimizu M, Ishiguro T: Treatment of tardive dystonia with an antispastic agent. Acta Psychiatr Scand; 98(4):341-3, 1998
Shapleske J, Mickay AP, Mckenna PJ Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry;168(4):516-8, 1996
Steen VW, Lovelie R, MacEwan T, et al: Dopamine D3-receptor gene variant and succeptability to tardive dyskinesia: Mol Psychiatry; 2(2):139-45, 1997
Sutcher H, Soderstrom J, Perry RD:Tardive dyskinesia: dental prosthetic therapy. Panminerva Med;40(2):154-6,1998
Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S An open-label study of botulinum toxin A for treatment oftardive dystonia. Clin Neuropharmacol; 20(1):90
-93,1997
Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT, Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Am J Psychiatry;
155(9):1207-13,1998
Tu JB, Psychopharmacogenic basis of medication induced movement disorders. International Clinical Psychopharmacology; 12: 1-12, 1997
Wirshing DA, Bartzokis G, Wirshing WC, et al: Tardive dyskinesia and serum iron indices. Biol Psychiatry; 44(5):493-8, 1998
Woerner MG, Saltz BL, Kane JM, et al: Diabetes and development of tardive dyskinesia. Am J Psychiatry; 150(6):966-8, 1993
|
|